SWA
ALNY icon

SOA Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

SOA Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Hold
36
– – ﹤0.01% 602
2026
Q1 		$11.9K Hold
36
– – ﹤0.01% 565
2025
Q4 		$14.3K Hold
36
– – ﹤0.01% 549
2025
Q3 		$16.4K Buy
+36
New +$14.7K ﹤0.01% 549

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOA Wealth Advisors's ALNY Position: Q2 2026 in Review

SOA Wealth Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 36 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #602.

SOA Wealth Advisors first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $16.4K in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SOA Wealth Advisors held 36 shares of Alnylam Pharmaceuticals worth $10.8K as of Q2 2026.
  • SOA Wealth Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SOA Wealth Advisors's portfolio in Q2 2026, its #602 holding.
  • SOA Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • SOA Wealth Advisors's Alnylam Pharmaceuticals position peaked at $16.4K in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SOA Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.